Rxo (RXO) Enterprise Value (2022 - 2026)

Rxo (RXO) has reported Enterprise Value for 5 consecutive years, with $4.5 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 77.18% year-over-year to $4.5 billion; the trailing twelve-month figure through Jun 2026 stood at $4.5 billion (up 77.18% YoY), and the FY2025 full-year result was $2.1 billion, down 34.57% from the prior year.
• Enterprise Value advanced to $4.5 billion in Q2 2026 per RXO's latest filing, from $2.4 billion in the prior quarter.
• Across five years, Enterprise Value topped out at $4.5 billion in Q2 2026 and bottomed at $1.9 billion in Q4 2022.
• Historically, Enterprise Value has averaged $2.8 billion across 5 years, with a median of $2.6 billion in 2025.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value soared 101.73% in 2024, then plunged 43.81% in 2025.
• Over 5 years, Enterprise Value stood at $1.9 billion in 2022, then jumped by 42.69% to $2.7 billion in 2023, then increased by 15.77% to $3.1 billion in 2024, then tumbled by 34.57% to $2.1 billion in 2025, then soared by 120.37% to $4.5 billion in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $4.5 billion, $2.4 billion, and $2.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.